



# PRACTICE BULLETIN

CLINICAL MANAGEMENT GUIDELINES FOR OBSTETRICIAN—GYNECOLOGISTS

NUMBER 119, APRIL 2011

## Female Sexual Dysfunction

*Female sexual dysfunction encompasses a number of conditions that are characterized by one of the following symptoms: loss of sexual desire, impaired arousal, inability to achieve orgasm, or sexual pain. A diagnosis of female sexual dysfunction is made when symptoms are sufficient to result in personal distress (1, 2). The adverse effect of female sexual dysfunction on the quality of life of affected women can extend into interpersonal relationships and the workplace. In North American culture, female sexual dysfunction is prevalent but often neglected in the health care setting because women are unlikely to discuss it with their health care providers unless asked (2). Talking about sexual function with patients may elicit anxiety in the physician and patient. Obstacles to discussing sexual health include a lack of adequate training and confidence in the topic, few perceived treatment options, inadequate clinical time to obtain a sexual history, patients' reluctance to initiate the conversation, and the underestimation of the prevalence of sexual dysfunction (3). The purpose of this document is to describe the basics of this disorder, including the physiology of the normal female sexual response; outline the criteria for diagnosis as listed in the Diagnostic and Statistical Manual of Mental Disorders: DSM-IV-TR, fourth edition, text revision (DSM-IV-TR); highlight current management strategies based on available evidence; and target areas that require more study.*

### Background

During the 1950s, Kinsey and colleagues published landmark studies of sexual practices in the United States that examined the sexual lives of females (4). Masters and Johnson subsequently pioneered research efforts that expanded our scientific knowledge of the sexual response (5). They identified four physiologic stages of the sexual response: 1) excitement, 2) plateau, 3) orgasm, and 4) resolution. These stages are basic biologic responses influenced by psychologic, environmental, and physiologic factors. Later, a three-phase model was developed, consisting of 1) desire, 2) arousal, and 3) orgasm (6). A more complex, nonlinear model of female sexual response also has been proposed that integrates emotional intimacy, sexual stimuli, and relationship satisfaction (2).

Desire and arousal are difficult to distinguish as distinct entities, and desire does not always precede arousal. For many women, a sexual encounter may begin without any desire initially present. According to the *DSM-IV-TR*, sexual dysfunction generally is characterized as any sexual complaint or problem resulting from disorders of desire, arousal, orgasm, or sexual pain that causes marked distress or interpersonal difficulty (1). Because more than one female sexual dysfunction may exist in the same patient, it is important that the clinician determine which is the primary female sexual dysfunction and how comorbid female sexual dysfunctions evolved over time.

### Normal Sexual Response

Sexual arousal in women results in increased genital blood flow, swelling of the labia and vaginal walls, release

---

**Committee on Practice Bulletins—Gynecology.** This Practice Bulletin was developed by the Committee on Practice Bulletins—Gynecology with the assistance of John Buster, MD; Sheryl Kingsberg, PhD; and Charles Kilpatrick, MD. The information is designed to aid practitioners in making decisions about appropriate obstetric and gynecologic care. These guidelines should not be construed as dictating an exclusive course of treatment or procedure. Variations in practice may be warranted based on the needs of the individual patient, resources, and limitations unique to the institution or type of practice.

of lubricating secretions from the genital tract, and transudation from the subepithelial vasculature. Vulvar blood flow increases from active neurogenic dilation of sinusoidal blood spaces in the corporal tissue of the clitoris, vestibular bulbs, and spongiosal tissue surrounding the urethra (2, 7). Pelvic nerve stimulation results in clitoral smooth muscle relaxation and arterial smooth muscle dilation. With increasing arousal, clitoral artery inflow increases clitoral intracavernous pressure, which causes tumescence and protrusion of the clitoris (2, 7).

Central neuroendocrine mechanisms that regulate female sexual response are described today as a dynamic process, creating a balance between excitatory and inhibitory factors (2, 7, 8). Desire is believed to be triggered in the hypothalamus by the activation of the dopamine system (9–11). Research suggests that increased activity of the dopamine system occurs early in the sexual response and may propagate to and activate other areas of the brain, including the limbic system (11, 12). The noradrenergic system is believed to be involved in sexual arousal through the initiation of autonomic sensations of excitement with increased heart rate and increasing blood pressure (both systolic and diastolic) (13, 14). Orgasm is a transient peak sensation of intense pleasure and can be described as a reflex with rhythmic contractions of the perineal, bulbocavernosus, and pubococcygeus muscles, with a sudden release of endogenous opioids, serotonin, prolactin, and oxytocin (15, 16). Resolution has been

associated with increased brain serotonergic activity and decreased dopamine release (11).

## Types of Sexual Dysfunction


Female sexual dysfunction conditions can be categorized as sexual desire disorders, sexual arousal disorder, orgasmic disorder, or sexual pain disorders.

### Sexual Desire Disorders

Hypoactive sexual desire disorder and sexual aversion disorder comprise the sexual desire disorders. According to the *DSM-IV-TR*, *hypoactive sexual desire disorder* is defined as a persistent or recurrent deficiency or absence of sexual desire or receptivity to sexual activity that causes marked distress or interpersonal difficulty (1). *Sexual aversion disorder* is defined as a persistent or recurrent aversive response to genital contact with a sexual partner that causes distress or interpersonal difficulty (1).

Hypoactive sexual desire disorder is the most common female sexual dysfunction, with an estimated prevalence rate ranging between 5.4% and 13.6% (Fig. 1) (17, 18). One study reported an 8.3% prevalence of hypoactive sexual desire disorder based on a representative sample of almost 2,000 U.S. women aged 30–70 years (19).

Hypoactive sexual desire disorder reaches a peak in women aged 40–60 years (Fig. 1) and in individuals that have undergone surgical menopause (17, 19). In this age group, the disorder can be linked to situational circum-



**Figure 1.** Prevalence of sexual problems associated with sexually related personal distress by 10-year age bands. Filled circle, desire; open triangle, arousal; filled square, orgasm; open diamond, any. (Shifren JL, Monz BU, Russo PA, Segreti A, Johannes CB. Sexual problems and distress in United States: prevalence and correlates. *Obstet Gynecol* 2008;112:970–8.)

stances, such as chronic disease, depression, or medication use, but more often is diagnosed as an isolated event (20–26). Atrophic vaginitis and pelvic floor surgery can lead to dyspareunia and sexual aversion and lost sexual desire (2). Women with endocrine problems and adrenal insufficiency also frequently experience hypoactive sexual desire disorder (27, 28).

In young women, hypoactive sexual desire disorder frequently is associated with situational circumstances, such as dysfunctional interpersonal relationships, chronic disease, depression, use of certain medications, gynecologic disorders, or other mitigating factors (20, 21). Use of antidepressants, particularly selective serotonin reuptake inhibitors (SSRIs), oral contraceptives, and corticosteroids can be associated with hypoactive sexual desire disorder (29–32).

The prevalence of sexual aversion disorder is not well established. Painful or traumatic life events may give rise to sexual aversion. Because many women with this disorder avoid sexual contact, the disorder may remain undiagnosed unless it surfaces as part of a dysfunctional relationship (33, 34). Treatment consists of psychotherapy and antidepressants for patients who have associated anxiety.

### Female Sexual Arousal Disorder

*Female sexual arousal disorder* refers to an inability to complete sexual activity with adequate lubrication that causes marked distress or interpersonal difficulty (1). The results from a survey of a national research panel representative of U.S. women indicate that 5% of these women have significant difficulty with sexual arousal (17). Because female sexual arousal disorder frequently is linked to a gynecologic or chronic medical condition or the use of certain medications, it typically resolves when the inciting disorder is successfully treated or the medication is adjusted. Medications, particularly SSRIs, are commonly associated with female sexual arousal disorder (35, 36). Female sexual arousal disorder also may be associated with atrophic vaginitis after spontaneous menopause or oophorectomy, which causes pain with vaginal penetration and difficulties in lubrication that impair sexual arousal.

### Female Orgasmic Disorder

The *DSM-IV-TR* defines *female orgasmic disorder* as a persistent or recurrent delay in or absence of orgasm after a normal excitement phase, which causes marked distress or interpersonal difficulty (1). Female orgasmic disorder has a reported prevalence of 3.4–5.8 % (17).

Primary orgasmic disorder is defined as never having the ability to achieve orgasm. Women with primary orgasmic disorder usually have normal levels of sexual

desire but are unable to achieve orgasm. Primary orgasmic disorder often is associated with a history of trauma or abuse or can have genetic origins, but it may have no explanation (37). It usually does not resolve on its own (38). In primary orgasmic disorder associated with abuse, psychotherapy and couples counseling may be helpful. After counseling, masturbation is an effective way for the woman who has never achieved orgasm to experience her first climax (15). There is no effective therapy for unexplained primary orgasmic disorder in which the patient has never achieved orgasm even through masturbation.

Secondary orgasmic disorder generally is the result of another sexual dysfunction. Secondary orgasmic disorder frequently is linked with hypoactive sexual desire disorder, having the same situational and psychosocial causes. It can be associated with pelvic surgery and medications, such as antidepressants. In women with orgasmic dysfunction, SSRIs are a commonly recognized cause (30, 31). A number of psychosocial factors, including age, social class, personality, and relationship status have been commonly related to orgasmic ability. Religious and cultural beliefs have been found to be negatively correlated with orgasmic ability, a finding that is believed to be due to individuals' feelings of excessive guilt about participating in sexual activity (15).

Treatment of the primary dysfunction frequently leads to restoration of the ability to achieve orgasm (15). Women are taught to be comfortable with their bodies as well as their own sexuality by altering negative attitudes and decreasing anxiety. Adjunctive education on self-pleasuring techniques generally is helpful. Behavioral treatments include masturbation instruction, communication exercises, sensate focus exercises, and systematic desensitization (39).

### Sexual Pain Disorders

Dyspareunia and vaginismus are two subcategories of sexual pain disorders. According to the *DSM-IV-TR*, *dyspareunia* is defined as recurrent or persistent genital pain associated with sexual intercourse that is not caused exclusively by lack of lubrication or by vaginismus and causes marked distress or interpersonal difficulty (1). The *DSM-IV-TR* defines *vaginismus* as recurrent or persistent involuntary spasm of the musculature of the outer third of the vagina that interferes with sexual intercourse, causing marked distress or interpersonal difficulty (1).

Dyspareunia is a common sexual problem, particularly in postmenopausal women in which prevalence ranges from 8% to 22% (40, 41). Recent perspectives suggest that dyspareunia may be characterized as a pain

disorder that interferes with sexuality rather than as a sexual disorder characterized by pain. Therefore, dyspareunia is believed to be a specific pain disorder with interdependent psychologic and biologic contributions and context-dependent etiologies (38). Pain on vaginal entry typically is reflective of provoked vestibulodynia, inadequate lubrication, or vaginismus. Physical examination will reproduce the pain when the vulva or vagina is touched with a cotton swab or when a finger is inserted into the vagina. Palpation of the walls of the vagina, uterus, and urethral structures can help identify physiologic contributions. Identification of the initiating and maintaining factors is fundamental to the diagnostic process. Loss of desire and arousal disorders associated with dyspareunia may contribute to the worsening of pain over time because the lack of genital arousal paired with sexual activity often results in physical discomfort (2, 38). The differential diagnosis is broad (Table 1).

Vaginismus is a relatively uncommon problem with prevalence rates ranging from 1% to 6% (2). In some women, vaginismus occurs because pain is anticipated (38). For some women, vaginismus is limited to sexual activity, whereas in others it is related only to fear of pelvic examination. Some women enjoy sexual activity and achieve orgasm, but still have vaginismus; they cannot consummate intercourse because vaginal penetration is not possible (2, 33, 38). Vaginismus frequently is linked to hypoactive sexual desire disorder and sexual aversion. These disorders often have the same situational and psychosocial causes and resolve in response to treatment of those conditions. In other cases, vaginismus is linked to gynecologic disorders, chronic medical conditions, or the use of certain medications, and it resolves with treatment or medication adjustment (2, 33, 38, 40).

**Table 1. Conditions Associated With Sexual Pain**

Superficial	Deep
Provoked vestibulodynia	Endometriosis
	Pelvic congestion syndrome
Vulvodynia	Interstitial cystitis
Chronic vulvar dermatoses	Uterine retroversion
Vulvitis or vulvovaginitis	Uterine leiomyomas
Condylomas	Adenomyosis
Dermatologic disease (infectious or noninfectious)	Pelvic inflammatory disease
	Pelvic adhesive disease
	Ovarian remnant syndrome
	Irritable bowel syndrome
	History of sexual abuse

Modified from Boardman LA, Stockdale CK. Sexual pain. Clin Obstet Gynecol 2009;52:682–90.

The most effective treatment is a combination of cognitive and behavioral psychotherapy, typically referred to as systematic desensitization. Women are taught deep muscle relaxation techniques, which they then use during exercises in which they are instructed to very gradually insert objects (usually dilators) of increasing diameter into the vagina. The goal is to desensitize a woman to her fear that vaginal penetration will be painful and to enable her to gain a sense of control over a sexual encounter or a pelvic examination, so that vaginal muscle contractions no longer occur as an automatic defense to vaginal penetration. If treatment is not progressing, referral for pelvic floor physical therapy often is helpful (2, 33, 38).

## Clinical Considerations and Recommendations

### ► *What is the initial approach to a patient who presents with a possible sexual dysfunction?*

A physician who is comfortable with the topic, knows and has seen the patient before, is caring and compassionate, and seems concerned about sexual wellness is one with whom patients will feel comfortable discussing sexual concerns (42). The initial approach begins with obtaining a sexual history during the review of symptoms. A very brief set of questions can suffice or the patient can complete a screening questionnaire (4, 43). The Brief Sexual Symptom checklist for women was developed by the International Consultation in Sexual Medicine as a primary screening tool and may be helpful (see Box 1). A questionnaire provides an opportunity to let the patient know that discussing sexual health is important and appropriate. Taking a thorough sexual history includes recording the patient's medical, surgical, social, and psychiatric history (2, 43–45). Information about the use of prescription and over-the-counter medications should be elicited and a complete gynecologic evaluation performed, targeting areas that were uncovered in the sexual function history. After initial evaluation, treatment can be initiated or, depending on the comfort level and training of the physician, a referral can be made to a trained specialist, such as a marriage counselor or sex therapist.

### ► *Which medications are associated with female sexual dysfunction?*

Numerous medications, both prescription and over-the-counter, have been associated with sexual dysfunction. Psychotropic medications, antihypertensives, histamine

**Box 1. Brief Sexual Symptom Checklist for Women**

Please answer the following questions about your overall sexual function:

1. Are you satisfied with your sexual function?

Yes  No

If no, please continue.

2. How long have you been dissatisfied with your sexual function?

3a. The problem(s) with your sexual function is: (mark one or more)

- 1 Problem with little or no interest in sex  
 2 Problem with decreased genital sensation (feeling)  
 3 Problem with decreased vaginal lubrication (dryness)  
 4 Problem reaching orgasm  
 4 [5] Problem with pain during sex  
 5 [6] Other:

3b. Which problem is most bothersome (circle)

1 2 3 4 5 [6]

[The problems were misnumbered in the source publication.—Ed.]

4. Would you like to talk about it with your doctor?

Yes  No

Reprinted from Hatzichristou D, Rosen RC, Derogatis LR, Low WY, Meuleman EJ, Sadovsky R, et al. Recommendations for the clinical evaluation of men and women with sexual dysfunction. *J Sex Med* 2010;7:337–48. Review.

blockers, and hormonal medications also have been implicated.

The most common medications linked to sexual dysfunction are the SSRIs. The most frequently reported problems are orgasmic dysfunction, decreased sexual desire, and decreased arousal (36). Compounding this side effect is the fact that depressed women tend to have sexual dysfunction before treatment begins (46). Decreasing the dosage of a medication sometimes may help alleviate some of these problems. Switching to another antidepressant may alleviate symptoms, but other antidepressant classes also have been associated with sexual dysfunction. Although a structured treatment interruption may be helpful in some patients, it is not an option in some other patients because of underlying psychiatric concerns. Consultation with a health care provider with expertise in psychiatric medications who can assist in distinguishing baseline female sexual dysfunction from dysfunction resulting from treatment

of depression may be helpful. A medication adjustment with long-term follow-up may be important for improved sexual functioning.

► ***What is the effect of hysterectomy on sexual function? What is the effect of supracervical hysterectomy on postoperative sexual function compared with hysterectomy with removal of the cervix?***

The main indications for hysterectomy in the United States are uterine leiomyomas, menstrual disorders, uterine prolapse, and endometriosis—all of which can lead to a decreased quality of life and sexual dysfunction (47). Aside from the risks inherent in the surgery itself, anxiety about sexual function after surgery is high (48, 49).

Postoperative dyspareunia, resulting from shortening vaginal length at the time of abdominal hysterectomy; postoperative scarring of the vagina, resulting from vaginal dryness; and the possibility that orgasm would not be as strong or pleasurable without a uterus have been proposed as reasons for decreased sexual function postoperatively (50–52). However, there are many prospective studies that document improved dyspareunia rates after hysterectomy, regardless of operative route (53–57).

In general, prospective studies constructed to address the effect of hysterectomy on postoperative sexual function have failed to show a difference in total versus subtotal hysterectomy (57–60). One study of sexual satisfaction reported similar rates preoperatively and 1 year postoperatively by women, irrespective of type of hysterectomy performed (59). A second study comparing supracervical hysterectomy and total abdominal hysterectomy reported similar findings in the frequency of intercourse, frequency of orgasm, and rating of sexual relationship with a partner measured preoperatively and postoperatively for women in both groups (58). In a third study, there were no differences between the supracervical hysterectomy and the total abdominal hysterectomy groups in sexual functioning and measurement of health-related quality of life, including sexual desire, orgasm frequency and quality, and body image, measured 2 years after surgery (60).

► ***What is the role of estrogen therapy on sexual function?***

The results of recently conducted hormonal supplementation studies have prompted clinicians to re-evaluate universal estrogen use in postmenopausal women, in oral or topical form (61). Estrogen affects sexual perfor-

mance through maintenance of genital tissues and secretions, pelvic muscle tone, and elasticity. The addition of topical estrogen to the vagina can aid lubrication by reducing intercellular space resistance and can improve fluid flow through the epithelium (62). Vaginal estrogen for the treatment of postmenopausal atrophy results in improved dyspareunia, less vaginal dryness, improved vaginal mucosal maturation indices, and reduced vaginal pH (63). Genital estrogen effects are best understood by the consequences of their absence. Estradiol secretion is variable during perimenopausal years and decreases to very low levels after menopause. Estrogen withdrawal increases tissue fragility, rates of vaginal and urinary infections, irritation, dryness, urogenital pain, and susceptibility to vaginal tissue trauma (7, 16, 64). Decreasing estrogen levels induce vulvovaginal atrophy leading to sexual pain and trauma during intercourse.

Oral forms of estrogen may not alleviate vulvovaginal atrophy and topical estrogen may be required (65). For vulvovaginal atrophy leading to sexual dysfunction, topical estrogen formulations are the most effective (65, 66). Tablets, gels, creams, and vaginal rings appear to be equally effective, and selection of an estrogen formulation should incorporate patient's preference (67). Systemic absorption of vaginal estrogen is limited, but still a concern because serum levels of estrogen in a treated patient are higher than in the nontreated patient. The lowest effective dose should be used for the least amount of time to alleviate symptoms (23, 68). The duration of treatment has not been determined, but some experts advocate daily treatment for a period of a few weeks, tapering down after this period based on symptoms (69).

Nonestrogen lubricants also may be useful for those women who cannot or choose not to take estrogen. These water-based or silicone-based lubricants and moisturizers do not address underlying causes of sexual dysfunction, but may be helpful in reducing or alleviating dyspareunia.

► ***In women with orgasmic disorders, what is the evidence for the efficiency of vasoactive medications (ie, sildenafil)?***

Sildenafil citrate is believed to increase pelvic blood flow to the clitoris and vagina similar to that in men who are being treated for erectile dysfunction. In randomized clinical trials of women being treated for sexual arousal disorder, the results have been contradictory (32, 70–72). Clinical trials of sildenafil were conducted to address the lack of vasocongestion. Vaginal engorgement in the presence of sexual stimuli was demonstrated with the use of sildenafil, but subjective experience of arousal

was not reliably achieved. One study of 98 women treated for depression with an SSRI compared sildenafil with placebo to improve orgasmic dysfunction and noted an improvement in Clinical Global Impression Sexual function scores in the sildenafil group (73). However, additional research is needed before a recommendation can be made for the use of sildenafil for the treatment of female sexual dysfunction.

► ***What is the evidence for the safety and efficacy of devices to treat arousal disorders?***

One battery-powered device intended for clitoral therapy has received approval from the U.S. Food and Drug Administration (FDA). This device is applied directly over the clitoris to create a vacuum to increase blood flow and engorgement (74). Several small pilot studies have evaluated its efficacy in improving orgasm, vaginal lubrication, genital sensation, and sexual satisfaction (75). This device may be best suited for women with arousal and orgasm difficulties, and no adverse outcomes from use of the device have been noted.

► ***What formulations and what routes of administration are preferred for androgen therapy in the treatment of hypoactive sexual desire disorder?***

Androgen levels continue to decrease in reproductive-aged women until menopause, at which point no further decrease is observed (76, 77). Numerous studies have demonstrated that sexual desire and sexual activity increase with androgen supplementation, but there also are as many that are equivocal in this regard. There are little long-term prospective data on the use of androgen therapy for female sexual dysfunction. Testosterone, the most commonly used androgen replacement treatment, does not have FDA approval for the treatment of hypoactive sexual desire disorder (78). Transdermal testosterone has been shown to be effective for the short-term treatment of hypoactive sexual desire disorder in women, with little evidence to support long-term use (longer than 6 months) (78–87). There is no proven clinical utility to monitoring androgen levels before or during treatment (88, 89).

Transdermal testosterone delivered by a matrix patch is the most extensively studied of the systems. However, matrix patches are not approved by the FDA and, therefore, are not available in the United States for the treatment of hypoactive sexual desire disorder (90). There are numerous randomized blinded clinical trials of the use of this matrix patch by nearly 3,000 postmenopausal women (in whom menopause occurred naturally or was surgically induced) with hypoactive sexual

desire disorder (78–86). All trials have demonstrated dose-related, significant increases in sexual desire with testosterone patches versus placebo when the dose was maintained at 300 micrograms per day or greater. All trials used a matrix patch that delivered testosterone at various doses (150 micrograms per day, 300 micrograms per day, or 450 micrograms per day), depending on the experimental design. The dosages investigated approximated the lower and higher limits of normal production of testosterone in premenopausal women. At 300 micrograms per day, consistent increases in sexual desire with few adverse effects were seen, but at 150 micrograms per day, the improvements were borderline. Side effects in these first 24-week trials were minimal and not different between groups except for patch site irritation and hirsutism, which was minor.

There are fewer studies of testosterone use in premenopausal women for the treatment of hypoactive sexual desire disorder. In a randomized controlled trial of 31 women (aged 31–45 years) using testosterone cream, those women showed statistically significant increases on validated self-reported sexual function scales at 12 weeks (91). In a larger trial of 261 women (aged 35–46 years), the use of testosterone spray, in three different doses, was shown to statistically increase sexually satisfying events with the higher two doses compared with placebo at 16 weeks (92).

Methyltestosterone, micronized testosterone, and dehydroepiandrosterone are available either off label or as customized formulations. However, there are limited, prospective, randomized high-quality clinical trial data on this treatment (93, 94). Consensus reports from the Endocrine Society and the North American Menopause Society have been cautionary (88, 89).

► ***What are the risks of androgen therapy, and how should patients be monitored?***

The main risks associated with androgen replacement therapy in women are hirsutism, acne, virilization, and cardiovascular (CV) complications. In addition, a possible association with breast cancer has been reported.

### **Hirsutism**

In studies in which women were administered testosterone for arousal disorders or vasocongestion difficulties, hirsutism, or unwanted hair growth, affected 3–20% of those treated (86, 93, 95, 96). In a large prospective trial of transdermal testosterone (placebo versus 150 micrograms versus 300 micrograms) for hypoactive sexual desire disorder, hair growth increased with increasing testosterone doses, although free testosterone levels had

little correlation with the degree of hirsutism, and the group that experienced increased hair growth was not more likely to discontinue therapy (86).

### **Acne**

Acne has been noted in less than 10% of patients who are treated with testosterone. In trials that compared testosterone plus estrogen with estrogen alone, there was no difference noted in acne prevalence (78, 81).

### **Virilization**

Virilization is uncommon and is mainly seen in supraphysiologic doses (97), with few women developing clitoromegaly, deepening of the voice, increase in muscle mass, and temporal balding in the dosages used for hypoactive sexual desire disorder treatment (78, 81). When virilization is noted in patients receiving smaller doses, the condition usually is reported as mild (86).

### **Cardiovascular Risk**

There are little prospective long-term data regarding adverse CV effects in women receiving testosterone for hypoactive sexual desire disorder (78). However, methyltestosterone combined with esterified estrogens has been associated with significant decreases in high-density lipoprotein (HDL) cholesterol and increased total cholesterol-to-HDL ratio but a significant decrease in triglycerides (98). There are little prospective long-term data regarding adverse CV effects in women receiving testosterone for hypoactive sexual desire disorder (78). In female-to-male transsexuals taking supraphysiologic doses of testosterone (160 mg/d of oral testosterone undecanoate), the risk of adverse CV effects (myocardial infarction, hypertension, and CV death) were no more than expected in the general male population (99).

Monitoring, consisting of serum lipid measurements and liver function tests in those women who are to begin androgen replacement seems reasonable. More long-term data in women receiving testosterone are needed to answer these questions.

### **Breast Cancer**

Breast cancer has been reported in a trial of the treatment of hypoactive sexual desire disorder, but it is unclear whether this was due to chance or if there is a causal relationship (86). The Women's Health Initiative observational trial reported a nonsignificant increase in the number of invasive breast cancer cases in those women taking testosterone and estrogen versus those in the control group (adjusted hazard ratio, 1.42; 95% confidence interval, 0.95–2.11) (100).

# Summary of Recommendations and Conclusions

*The following conclusion is based on good and consistent scientific evidence (Level A):*

- ▶ Transdermal testosterone has been shown to be effective for the short-term treatment of hypoactive sexual desire disorder, with little evidence to support long-term use (longer than 6 months).

*The following conclusions are based on limited or inconsistent scientific evidence (Level B):*

- ▶ Prospective studies constructed to address the effect of hysterectomy on postoperative sexual function have failed to show a difference in total versus subtotal hysterectomy.
- ▶ Vaginal estrogen for the treatment of postmenopausal atrophy results in improved dyspareunia, less vaginal dryness, improved vaginal mucosal maturation indices, and reduced vaginal pH.
- ▶ The main risks associated with androgen replacement therapy in women are hirsutism, acne, virilization, and CV complications. In addition, a possible association with breast cancer has been reported.

*The following conclusions are based primarily on consensus and expert opinion (Level C):*

- ▶ Female sexual dysfunction conditions can be categorized as sexual desire disorders, sexual arousal disorder, orgasmic disorder, and sexual pain disorders. Hypoactive sexual desire disorder is the most prevalent female sexual dysfunction.
- ▶ Obtaining a thorough sexual history includes recording the patient's medical, surgical, social, and psychiatric history.
- ▶ The most common medications linked to sexual dysfunction are the SSRIs. The most frequently reported problems are orgasmic dysfunction, decreased sexual desire, and decreased arousal.
- ▶ There is no proven clinical utility to monitoring androgen levels before or during the treatment for hypoactive sexual desire disorder.
- ▶ After initial evaluation, treatment can be initiated or, depending on the comfort level and training of the physician, a referral can be made to a trained specialist, such as a marriage counselor or sex therapist.

# Resources

Resources listed are for information purposes only. Referral to these resources and web sites does not imply the endorsement of the American College of Obstetricians and Gynecologists. Further, the American College of Obstetricians and Gynecologists does not endorse any commercial products that may be advertised or available from these organizations or on these web sites. These lists are not meant to be comprehensive. The exclusion of a resource or web site does not reflect the quality of that source or site. Please note that web sites and URLs are subject to change without notice.

American Association of Sexuality Educators,  
Counselors and Therapists

<http://www.aasect.org>

The American Congress of Obstetricians and  
Gynecologists

Web Treats: Sex and Sexuality

[http://www.acog.org/departments/dept\\_notice.cfm?  
recno=20&bulletin=3344](http://www.acog.org/departments/dept_notice.cfm?recno=20&bulletin=3344)

American Society for Reproductive Medicine

<http://www.asrm.org>

Kinsey Institute

<http://www.indiana.edu/~kinsey>

International Society for the Study of Women's  
Sexual Health

<http://www.isswsh.org>

North American Menopause Society

<http://www.menopause.org>

Society for the Scientific Study of Sexuality (SSSS)

<http://www.sexscience.org>

American Physical Therapy Association

<http://www.apta.org>

# References

1. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th ed. Text rev. Washington, DC: APA; 2000. (Level III)
2. Basson R. Sexuality and sexual disorders. Clin Update Womens Health Care 2003;II(2):1-94. (Level III)
3. Kingsberg SA. Taking a sexual history. Obstet Gynecol Clin North Am 2006;33:535-47. (Level III)
4. Kinsey AC. Sexual behavior in the human female. Philadelphia (PA): Saunders; 1953. (Level III)
5. Masters WH, Johnson VE. Human sexual response. Boston (MA): Little, Brown and Company; 1966. (Level III)
6. Kaplan HS. Disorders of sexual desire and other new concepts and techniques in sex therapy. New York (NY): Simon and Schuster; 1979. (Level III)

7. Davis SR, Guay AT, Shifren JL, Mazer NA. Endocrine aspects of female sexual dysfunction. *J Sex Med* 2004; 1:82–6. (Level III)
8. Archer JS, Love-Geffen TE, Herbst-Damm KL, Swinney DA, Chang JR. Effect of estradiol versus estradiol and testosterone on brain-activation patterns in postmenopausal women. *Menopause* 2006;13:528–37. (Level III)
9. Gizewski ER, Krause E, Karama S, Baars A, Senf W, Forsting M. There are differences in cerebral activation between females in distinct menstrual phases during viewing of erotic stimuli: a fMRI study. *Exp Brain Res* 2006;174:101–8. (Level II-3)
10. Bartels A, Zeki S. The neural correlates of maternal and romantic love. *Neuroimage* 2004;21:1155–66. (Level III)
11. Lorrain DS, Riolo JV, Matuszewich L, Hull EM. Lateral hypothalamic serotonin inhibits nucleus accumbens dopamine: implications for sexual satiety. *J Neurosci* 1999;19:7648–52. (Level III)
12. Abraham GE. Ovarian and adrenal contribution to peripheral androgens during the menstrual cycle. *J Clin Endocrinol Metab* 1974;39:340–6. (Level III)
13. Jeong GW, Park K, Youn G, Kang HK, Kim HJ, Seo JJ, et al. Assessment of cerebrocortical regions associated with sexual arousal in premenopausal and menopausal women by using BOLD-based functional MRI. *J Sex Med* 2005;2:645–51. (Level II-3)
14. Exton MS, Bindert A, Kruger T, Scheller F, Hartmann U, Schedlowski M. Cardiovascular and endocrine alterations after masturbation-induced orgasm in women. *Psychosom Med* 1999;61:280–9. (Level III)
15. Meston CM, Levin RJ, Sipski ML, Hull EM, Heiman JR. Women's orgasm. *Annu Rev Sex Res* 2004;15:173–257. (Level III)
16. Shifren JL, Schiff I. Role of hormone therapy in the management of menopause. *Obstet Gynecol* 2010;115:839–55. (Level III)
17. Shifren JL, Monz BU, Russo PA, Segreti A, Johannes CB. Sexual problems and distress in United States women: prevalence and correlates. *Obstet Gynecol* 2008;112:970–8. (Level II-3)
18. Segraves R, Woodard T. Female hypoactive sexual desire disorder: History and current status. *J Sex Med* 2006;3:408–18. (Level III)
19. West SL, D'Aloisio AA, Agans RP, Kalsbeek WD, Borisov NN, Thorp JM. Prevalence of low sexual desire and hypoactive sexual desire disorder in a nationally representative sample of US women. *Arch Intern Med* 2008;168:1441–9. (Level II-3)
20. Orentreich N, Brind JL, Rizer RL, Vogelmann JH. Age changes and sex differences in serum dehydroepiandrosterone sulfate concentrations throughout adulthood. *J Clin Endocrinol Metab* 1984;59:551–5. (Level II-3)
21. Rotter JI, Wong FL, Lifrak ET, Parker LN. A genetic component to the variation of dehydroepiandrosterone sulfate. *Metabolism* 1985;34:731–6. (Level III)
22. Crawford S, Santoro N, Laughlin GA, Sowers MF, McConnell D, Sutton-Tyrrell K, et al. Circulating dehydroepiandrosterone sulfate concentrations during the menopausal transition. *J Clin Endocrinol Metab* 2009;94:2945–51. (Level II-2)
23. Labrie F, Belanger A, Cusan L, Gomez JL, Candas B. Marked decline in serum concentrations of adrenal C19 sex steroid precursors and conjugated androgen metabolites during aging. *J Clin Endocrinol Metab* 1997;82:2396–402. (Level III)
24. Hornsby PJ. Biosynthesis of DHEAS by the human adrenal cortex and its age-related decline. *Ann N Y Acad Sci* 1995;774:29–46. (Level III)
25. Dennerstein L, Randolph J, Taffe J, Dudley E, Burger H. Hormones, mood, sexuality, and the menopausal transition. *Fertil Steril* 2002;77 (suppl 4):S42–8. (Level II-2)
26. Dennerstein L, Koochaki P, Barton I, Graziottin A. Hypoactive sexual desire disorder in menopausal women: a survey of Western European women. *J Sex Med* 2006;3:212–22. (Level II-3)
27. Johannsson G, Burman P, Wiren L, Engstrom BE, Nilsson AG, Ottosson M, et al. Low dose dehydroepiandrosterone affects behavior in hypopituitary androgen-deficient women: a placebo-controlled trial. *J Clin Endocrinol Metab* 2002;87:2046–52. (Level I)
28. Zang H, Davis SR. Androgen replacement therapy in androgen-deficient women with hypopituitarism. *Drugs* 2008;68:2085–93. (Level III)
29. Davis AR, Castano PM. Oral contraceptives and libido in women. *Annu Rev Sex Res* 2004;15:297–320. (Level III)
30. Stimmel GL, Gutierrez MA. Sexual dysfunction and psychotropic medications. *CNS Spectr* 2006;11:24–30. (Level III)
31. Montejo-Gonzalez AL, Llorca G, Izquierdo JA, Ledesma A, Bousono M, Calcedo A, et al. SSRI-induced sexual dysfunction: fluoxetine, paroxetine, sertraline, and fluvoxamine in a prospective, multicenter, and descriptive clinical study of 344 patients. *J Sex Marital Ther* 1997; 23:176–94. (Level II-3)
32. Caruso S, Intelisano G, Lupo L, Agnello C. Premenopausal women affected by sexual arousal disorder treated with sildenafil: a double-blind, cross-over, placebo-controlled study. *BJOG* 2001;108:623–8. (Level II-3)
33. Basson R. Female sexual response: the role of drugs in the management of sexual dysfunction [published erratum appears in *Obstet Gynecol* 2001;98:522]. *Obstet Gynecol* 2001;98:350–3. (Level III)
34. Kingsberg SA, Janata JW. Female sexual disorders: assessment, diagnosis, and treatment. *Urol Clin North Am* 2007;34:497–506, v–vi. (Level III)
35. Graziottin A. Iatrogenic and post-traumatic female sexual disorder. In: Porst H, Buvat J, editors. *Standard practice in sexual medicine*. Malden (MA): Blackwell; 2006. p. 351–61. (Level III)
36. Kennedy SH, Rizvi S. Sexual dysfunction, depression, and the impact of antidepressants. *J Clin Psychopharmacol* 2009;29:157–64. (Level III)
37. Dunn KM, Cherkas LF, Spector TD. Genetic influences on variation in female orgasmic function: a twin study. *Biol Lett* 2005;1:260–3. (Level II-3)

38. Binik YM, Reissing E, Pukall C, Flory N, Payne KA, Khalife S. The female sexual pain disorders: genital pain or sexual dysfunction? *Arch Sex Behav* 2002;31:425–9. (Level III)
39. McCabe MP. Anorgasmia in women. *J Fam Psychother* 2009;20:177–97. (Level III)
40. Steege JF, Zolnoun DA. Evaluation and treatment of dyspareunia. *Obstet Gynecol*. 2009;113:1124–36. (Level III)
41. Latthe P, Mignini L, Gray R, Hills R, Khan K. Factors predisposing women to chronic pelvic pain: systematic review. *BMJ* 2006;332:749–55. (Systematic Review)
42. Risen CB. A guide to taking a sexual history. *Psychiatr Clin North Am* 1995;18:39–53. (Level III)
43. Hatzichristou D, Rosen RC, Derogatis LR, Low WY, Meuleman EJ, Sadovsky R, et al. Recommendations for the clinical evaluation of men and women with sexual dysfunction. *J Sex Med* 2010;7:337–48. (Level III)
44. Tomlinson J. ABC of sexual health: taking a sexual history. *BMJ* 1998;317:1573–6. (Level III)
45. Kingsberg S. Just ask! Talking to patients about sexual function. *Sex Reprod Menopause* 2004;2:199–203. (Level III)
46. Hensley PL, Nurnberg HG. SSRI sexual dysfunction: a female perspective. *J Sex Marital Ther* 2002;28(suppl 1):143–53. (Level III)
47. Falcone T, Walters MD. Hysterectomy for benign disease. *Obstet Gynecol* 2008;111:753–67. (Level III)
48. Lalinec-Michaud M, Engelsmann F. Anxiety, fears and depression related to hysterectomy. *Can J Psychiatry* 1985;30:44–7. (Level III)
49. Dennerstein L, Wood C, Burrows GD. Sexual response following hysterectomy and oophorectomy. *Obstet Gynecol* 1977;49:92–6. (Level III)
50. Jewett JG. Vaginal length and incidence of dyspareunia following total abdominal hysterectomy. *Am J Obstet Gynecol* 1952;63:400–7. (Level III)
51. Kilkku P, Gronroos M, Hirvonen T, Rauramo L. Supravaginal uterine amputation vs. hysterectomy. Effects on libido and orgasm. *Acta Obstet Gynecol Scand* 1983;62:147–52. (Level II-3)
52. Oldenhave A, Jaszmann LJ, Haspels AA, Everaerd WT. Impact of climacteric on well-being. A survey based on 5213 women 39 to 60 years old. *Am J Obstet Gynecol* 1993;168:772–80. (Level II-3)
53. Kilkku P. Supravaginal uterine amputation vs. hysterectomy. Effects on coital frequency and dyspareunia. *Acta Obstet Gynecol Scand* 1983;62:141–5. (Level II-3)
54. Virtanen H, Makinen J, Tenho T, Kiilholma P, Pitkanen Y, Hirvonen T. Effects of abdominal hysterectomy on urinary and sexual symptoms. *Br J Urol* 1993;72:868–72. (Level III)
55. Helstrom L, Lundberg PO, Sorbom D, Backstrom T. Sexuality after hysterectomy: a factor analysis of women's sexual lives before and after subtotal hysterectomy. *Obstet Gynecol* 1993;81:357–62. (Level II-3)
56. Rhodes JC, Kjerulff KH, Langenberg PW, Guzinski GM. Hysterectomy and sexual functioning. *JAMA* 1999;282:1934–41. (Level II-2)
57. Zobbe V, Gimbel H, Andersen BM, Filtenborg T, Jakobsen K, Sorensen HC, et al. Sexuality after total vs. subtotal hysterectomy. *Acta Obstet Gynecol Scand* 2004;83:191–6. (Level I)
58. Thakar R, Ayers S, Clarkson P, Stanton S, Manyonda I. Outcomes after total versus subtotal abdominal hysterectomy. *N Engl J Med* 2002;347:1318–25. (Level I)
59. Gimbel H, Zobbe V, Andersen BM, Filtenborg T, Gluud C, Tabor A. Randomised controlled trial of total compared with subtotal hysterectomy with one-year follow up results. *BJOG* 2003;110:1088–98. (Level I)
60. Kuppermann M, Summitt RL Jr, Varner RE, McNeeley SG, Goodman-Gruen D, Learman LA, et al. Sexual functioning after total compared with supracervical hysterectomy: a randomized trial. Total or Supracervical Hysterectomy Research Group. *Obstet Gynecol* 2005;105:1309–18. (Level I)
61. Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. Writing Group for the Women's Health Initiative Investigators. *JAMA* 2002;288:321–33. (Level I)
62. Gorodeski GI. Aging and estrogen effects on transcervical-transvaginal epithelial permeability. *J Clin Endocrinol Metab* 2005;90:345–51. (Level III)
63. Ayton RA, Darling GM, Murkies AL, Farrell EA, Weisberg E, Selinus I, et al. A comparative study of safety and efficacy of continuous low dose oestradiol released from a vaginal ring compared with conjugated equine oestrogen vaginal cream in the treatment of postmenopausal urogenital atrophy. *Br J Obstet Gynaecol* 1996;103:351–8. (Level I)
64. Berman JR, Berman L, Goldstein I. Female sexual dysfunction: incidence, pathophysiology, evaluation, and treatment options. *Urology* 1999;54:385–91. (Level III)
65. Mac Bride MB, Rhodes DJ, Shuster LT. Vulvovaginal atrophy. *Mayo Clin Proc* 2010;85:87–94. (Level III)
66. Lara LA, Useche B, Ferriani RA, Reis RM, de Sa MF, de Freitas MM, et al. The effects of hypoestrogenism on the vaginal wall: interference with the normal sexual response. *J Sex Med* 2009;6:30–9. (Level III)
67. Suckling JA, Kennedy R, Lethaby A, Roberts H. Local oestrogen for vaginal atrophy in postmenopausal women. *Cochrane Database of Systematic Reviews* 2006, Issue 4. Art. No.: CD001500. DOI: 10.1002/14651858.CD001500.pub2. (Meta-analysis)
68. Notelovitz M, Funk S, Nanavati N, Mazzeo M. Estradiol absorption from vaginal tablets in postmenopausal women. *Obstet Gynecol* 2002;99:556–62. (Level I)
69. Bachmann GA. Influence of menopause on sexuality. *Int J Fertil Menopausal Stud* 1995;40(suppl 1):16–22. (Level III)

70. Berman JR, Berman LA, Toler SM, Gill J, Haughie S. Safety and efficacy of sildenafil citrate for the treatment of female sexual arousal disorder: a double-blind, placebo controlled study. Sildenafil Study Group. *J Urol* 2003;170:2333–8. (Level I)
71. Basson R, McInnes R, Smith MD, Hodgson G, Koppiker N. Efficacy and safety of sildenafil citrate in women with sexual dysfunction associated with female sexual arousal disorder. *J Womens Health Gend Based Med* 2002; 11:367–77.(Level I)
72. Basson R, Brotto LA. Sexual psychophysiology and effects of sildenafil citrate in oestrogenised women with acquired genital arousal disorder and impaired orgasm: a randomised controlled trial. *BJOG* 2003;110:1014–24. (Level I)
73. Nurnberg HG, Hensley PL, Heiman JR, Croft HA, Debattista C, Paine S. Sildenafil treatment of women with antidepressant-associated sexual dysfunction: a randomized controlled trial. *JAMA* 2008;300:395–404. (Level I)
74. Wilson SK, Delk JR 2nd, Billups KL. Treating symptoms of female sexual arousal disorder with the Eros-Clitoral Therapy Device. *J Gend Specif Med* 2001;4:54–8. (Level III)
75. Billups KL. The role of mechanical devices in treating female sexual dysfunction and enhancing the female sexual response. *World J Urol* 2002;20:137–41. (Level III)
76. Burger HG, Papalia MA. A clinical update on female androgen insufficiency--testosterone testing and treatment in women presenting with low sexual desire. *Sex Health* 2006;3:73–8. (Level III)
77. Davison SL, Bell R, Donath S, Montalto JG, Davis SR. Androgen levels in adult females: changes with age, menopause, and oophorectomy. *J Clin Endocrinol Metab* 2005;90:3847–53. (Level II-3)
78. Braunstein GD, Sundwall DA, Katz M, Shifren JL, Buster JE, Simon JA, et al. Safety and efficacy of a testosterone patch for the treatment of hypoactive sexual desire disorder in surgically menopausal women: a randomized, placebo-controlled trial. *Arch Intern Med* 2005;165: 1582–9. (Level I)
79. Braunstein GD. Safety of testosterone treatment in postmenopausal women. *Fertil Steril* 2007;88:1–17. (Level III)
80. Braunstein GD. Management of female sexual dysfunction in postmenopausal women by testosterone administration: safety issues and controversies. *J Sex Med* 2007; 4:859–66. (Level III)
81. Buster JE, Kingsberg SA, Aguirre O, Brown C, Breau JG, Buch A, et al. Testosterone patch for low sexual desire in surgically menopausal women: a randomized trial. *Obstet Gynecol* 2005;105:944–52. (Level I)
82. Simon J, Braunstein G, Nachtigall L, Utian W, Katz M, Miller S, et al. Testosterone patch increases sexual activity and desire in surgically menopausal women with hypoactive sexual desire disorder. *J Clin Endocrinol Metab* 2005;90:5226–33. (Level I)
83. Davis SR, van der Mooren MJ, van Lunsen RH, Lopes P, Ribot C, Rees M, et al. Efficacy and safety of a testosterone patch for the treatment of hypoactive sexual desire disorder in surgically menopausal women: a randomized, placebo-controlled trial [published erratum appears in *Menopause* 2006;13:850]. *Menopause* 2006;13:387–96. (Level I)
84. Shifren JL, Davis SR, Moreau M, Waldbaum A, Bouchard C, DeRogatis L, et al. Testosterone patch for the treatment of hypoactive sexual desire disorder in naturally menopausal women: results from the INTIMATE NM1 Study [published erratum appears in *Menopause* 2007;14:157]. *Menopause* 2006;13:770–9.(Level I)
85. Davis SR, McCloud P, Strauss BJ, Burger H. Testosterone enhances estradiol's effects on postmenopausal bone density and sexuality. *Maturitas* 2008;61:17–26. (Level I)
86. Davis SR, Moreau M, Kroll R, Bouchard C, Panay N, Gass M, et al. Testosterone for low libido in postmenopausal women not taking estrogen. *APHRODITE Study Team. N Engl J Med* 2008;359:2005–17. (Level I)
87. Nachtigall L, Casson P, Lucas J, Schofield V, Melson C, Simon JA. Safety and tolerability of testosterone patch therapy for up to 4 years in surgically menopausal women receiving oral or transdermal oestrogen. *Gynecol Endocrinol* 2011;27:39–48. (Level I)
88. The role of testosterone therapy in postmenopausal women: position statement of The North American Menopause Society. *North American Menopause Society. Menopause* 2005;12:496–511; quiz 649. (Level III)
89. Wierman ME, Basson R, Davis SR, Khosla S, Miller KK, Rosner W, et al. Androgen therapy in women: an Endocrine Society Clinical Practice guideline. *J Clin Endocrinol Metab* 2006;91:3697–710. (Level III)
90. Seibel MM. Men, women, and testosterone: why did the FDA fail Intrinsic? *Sex Reprod Menopause* 2005;3:1–2. (Level III)
91. Goldstat R, Briganti E, Tran J, Wolfe R, Davis SR. Transdermal testosterone therapy improves well-being, mood, and sexual function in premenopausal women. *Menopause* 2003;10:390–8. (Level II-3)
92. Davis S, Papalia MA, Norman RJ, O'Neill S, Redelman M, Williamson M, et al. Safety and efficacy of a testosterone metered-dose transdermal spray for treating decreased sexual satisfaction in premenopausal women: a randomized trial. *Ann Intern Med* 2008;148:569–77. (Level I)
93. Lobo RA, Rosen RC, Yang HM, Block B, Van Der Hoop RG. Comparative effects of oral esterified estrogens with and without methyltestosterone on endocrine profiles and dimensions of sexual function in postmenopausal women with hypoactive sexual desire. *Fertil Steril* 2003;79: 1341–52. (Level I)
94. Labrie F, Archer D, Bouchard C, Fortier M, Cusan L, Gomez JL, et al. High internal consistency and efficacy of intravaginal DHEA for vaginal atrophy. *Gynecol Endocrinol* 2010;26:524–32. (Level I)
95. Sherwin BB. Use of combined estrogen-androgen preparations in the postmenopause: evidence from clinical studies. *Int J Fertil Womens Med* 1998;43:98–103. (Level III)
96. Barrett-Connor E, Timmons C, Young R, Wiita B. Interim safety analysis of a two-year study comparing oral

estrogen-androgen and conjugated estrogens in surgically menopausal women. *Estratrust Working Group. J Womens Health* 1996;5:593–602. (Level III)

97. Urman B, Pride SM, Yuen BH. Elevated serum testosterone, hirsutism, and virilism associated with combined androgen-estrogen hormone replacement therapy. *Obstet Gynecol* 1991;77:595–8. (Level III)
98. Chiuvè SE, Martin LA, Campos H, Sacks FM. Effect of the combination of methyltestosterone and esterified estrogens compared with esterified estrogens alone on apolipoprotein CIII and other apolipoproteins in very low density, low density, and high density lipoproteins in surgically postmenopausal women. *J Clin Endocrinol Metab* 2004;89:2207–13. (Level I)
99. van Kesteren PJ, Asscheman H, Megens JA, Gooren LJ. Mortality and morbidity in transsexual subjects treated with cross-sex hormones. *Clin Endocrinol* 1997;47:337–42. (Level II-3)
100. Ness RB, Albano JD, McTiernan A, Cauley JA. Influence of estrogen plus testosterone supplementation on breast cancer. *Arch Intern Med* 2009;169:41–6. (Level II-2)

The MEDLINE database, the Cochrane Library, and the American College of Obstetricians and Gynecologists' own internal resources and documents were used to conduct a literature search to locate relevant articles published between January 1985–July 2010. The search was restricted to articles published in the English language. Priority was given to articles reporting results of original research, although review articles and commentaries also were consulted. Abstracts of research presented at symposia and scientific conferences were not considered adequate for inclusion in this document. Guidelines published by organizations or institutions such as the National Institutes of Health and the American College of Obstetricians and Gynecologists were reviewed, and additional studies were located by reviewing bibliographies of identified articles. When reliable research was not available, expert opinions from obstetrician–gynecologists were used.

Studies were reviewed and evaluated for quality according to the method outlined by the U.S. Preventive Services Task Force:

- I Evidence obtained from at least one properly designed randomized controlled trial.
- II-1 Evidence obtained from well-designed controlled trials without randomization.
- II-2 Evidence obtained from well-designed cohort or case–control analytic studies, preferably from more than one center or research group.
- II-3 Evidence obtained from multiple time series with or without the intervention. Dramatic results in uncontrolled experiments also could be regarded as this type of evidence.
- III Opinions of respected authorities, based on clinical experience, descriptive studies, or reports of expert committees.

Based on the highest level of evidence found in the data, recommendations are provided and graded according to the following categories:

Level A—Recommendations are based on good and consistent scientific evidence.

Level B—Recommendations are based on limited or inconsistent scientific evidence.

Level C—Recommendations are based primarily on consensus and expert opinion.

Copyright April 2011 by the American College of Obstetricians and Gynecologists. All rights reserved. No part of this publication may be reproduced, stored in a retrieval system, posted on the Internet, or transmitted, in any form or by any means, electronic, mechanical, photocopying, recording, or otherwise, without prior written permission from the publisher.

Requests for authorization to make photocopies should be directed to Copyright Clearance Center, 222 Rosewood Drive, Danvers, MA 01923, (978) 750-8400.

ISSN 1099-3630

**The American College of Obstetricians and Gynecologists  
409 12th Street, SW, PO Box 96920, Washington, DC 20090-6920**

Female sexual dysfunction. Practice Bulletin No. 119. American College of Obstetricians and Gynecologists. *Obstet Gynecol* 2011; 117:996–1007.